Peptide Reference

Peptide Terminology: The Words That Recur

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-232 cited sources

The short answer

A small set of terms recurs throughout peptide literature, residue, terminus, amidation, analogue, fragment, agonist, secretagogue. Each has a precise meaning, and several are used loosely in commercial writing in ways that change what is being claimed.

Key facts

Residue
An amino acid within a chain
N-terminus
The free-amine end
C-terminus
The carboxyl end
Amidation
C-terminal COOH replaced by CONH2
Analogue
Modified version of a parent
Fragment
A piece of a larger sequence
Agonist
Activates a receptor

The counting prefixes

Peptides are frequently named by length in Greek numerals, tripeptide, pentapeptide, heptapeptide, nonapeptide, pentadecapeptide for fifteen. Seeing pentadecapeptide in a paper title tells you the molecule's size before you read anything else, which is why the convention persists.

Analogue versus fragment

These are different and are often conflated. An analogue is a modified version of a parent molecule. Semaglutide is a GLP-1 analogue, with substitutions and a lipid chain. A fragment is a piece of a larger sequence, unmodified but incomplete. TB-500 is a fragment of thymosin beta-4. A molecule can be both: Modified GRF (1-29) is a fragment of GHRH that is also an analogue of that fragment.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £16.95

Why amidation is not cosmetic

Replacing a C-terminal carboxyl with an amide removes a negative charge and blocks carboxypeptidase attack. Many natural peptide hormones are amidated, so reproducing it in an analogue preserves both the native electrostatics and that protection. It also adds roughly 1 Da less than an unmodified terminus would give, which matters when checking a mass.

Agonist, antagonist and secretagogue

An agonist activates a receptor. An antagonist blocks it. A secretagogue prompts a gland to release something it already makes, which is a different kind of intervention from supplying the substance directly. The GIP paradox in the incretin literature (where an agonist and an antagonist both produce weight reduction) is a reminder that these labels describe mechanism rather than outcome.

Non-standard residues

Aib is α-aminoisobutyric acid, used to block peptidase access. D-amino acids are mirror images of the natural L forms and resist proteases that evolved for L backbones. Both appear in engineered peptides (ipamorelin contains one Aib and two D-residues) and neither can be written in single-letter code, which is itself a signal that a sequence is designed rather than natural.

Terms that carry a claim

Some names assert a function: body protection compound, delta sleep-inducing peptide, liver cell growth factor. These record what an investigator believed at discovery. They are hypotheses embedded in labels, and reading them as descriptions is the most common way a claim enters someone's thinking without ever being evaluated.

Frequently asked questions

What is the difference between an analogue and a fragment?

An analogue is a modified version of a parent; a fragment is an unmodified piece of a larger sequence. A molecule can be both.

Why are some peptides amidated?

It removes a C-terminal negative charge and blocks carboxypeptidase attack. Many natural peptide hormones are amidated.

What is a secretagogue?

A compound prompting a gland to release something it already produces, rather than supplying that substance directly.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Peptide Reference articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.